Ruben Pio

Ruben Pio

UNVERIFIED PROFILE

Are you Ruben Pio?   Register this Author

Register author
Ruben Pio

Ruben Pio

Publications by authors named "Ruben Pio"

Are you Ruben Pio?   Register this Author

79Publications

1154Reads

-Profile Views

Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.

Cancer Lett 2019 Jul 21;453:21-33. Epub 2019 Mar 21.

IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, 31008, Pamplona, Navarra, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, 31008, Pamplona, Navarra, Spain; CIBERONC, ISC-III, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.03.013DOI Listing
July 2019

Complement in Metastasis: A Comp in the Camp.

Front Immunol 2019 3;10:669. Epub 2019 Apr 3.

Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00669
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00669DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457318PMC
April 2019

Complementing the Cancer-Immunity Cycle.

Front Immunol 2019 12;10:774. Epub 2019 Apr 12.

Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00774DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473060PMC
April 2019

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.

J Thorac Oncol 2019 Mar 4;14(3):343-357. Epub 2018 Dec 4.

Solid Tumors Program, Centro de Investigación Médica Aplicada, Pamplona, Spain; Navarra Institute for Health Research, Pamplona, Spain; CIBERONC, Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.11.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494979PMC
March 2019

Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.

Semin Cell Dev Biol 2019 01 23;85:153-163. Epub 2017 Nov 23.

University of Navarra, Center for Applied Medical Research (CIMA), Program in Solid Tumors and Biomarkers, Pamplona, Spain; Navarra's Health Research Institute (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; University of Navarra, School of Sciences, Department of Biochemistry and Genetics, Pamplona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcdb.2017.11.023DOI Listing
January 2019

Comparison of RNA-seq and microarray platforms for splice event detection using a cross-platform algorithm.

BMC Genomics 2018 Sep 25;19(1):703. Epub 2018 Sep 25.

CEIT and Tecnun, University of Navarra, Parque Tecnológico de San Sebastián, Paseo Mikeletegi 48, 20009, San Sebastián, Gipuzkoa, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12864-018-5082-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156849PMC
September 2018

Complement C4d-specific antibodies for the diagnosis of lung cancer.

Oncotarget 2018 Jan 26;9(5):6346-6355. Epub 2017 Dec 26.

Program in Solid Tumors, Center for Applied Medical Research (CIMA), CIBERONC, and Navarra's Health Research Institute (IDISNA), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23690DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814217PMC
January 2018

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.

Oncotarget 2016 Dec;7(51):85063-85078

Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), Universidad Autónoma de Madrid, Cantoblanco, Madrid.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.13195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356720PMC
December 2016

A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Mol Oncol 2016 11 9;10(9):1437-1449. Epub 2016 Aug 9.

Program in Solid Tumors and Biomarkers, CIMA, 31008 Pamplona, Spain; Department of Biochemistry and Genetics, School of Science, University of Navarra, 31008 Pamplona, Spain; Navarra's Health Research Institute (IDISNA), 31008 Pamplona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2016.08.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423218PMC
November 2016

Innate immune mediators in cancer: between defense and resistance.

Immunol Rev 2016 11;274(1):290-306

Navarra Institute for Health Research (IDISNA), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12464DOI Listing
November 2016

A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer.

Clin Cancer Res 2016 07 3;22(13):3361-71. Epub 2016 Feb 3.

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2346DOI Listing
July 2016

EventPointer: an effective identification of alternative splicing events using junction arrays.

BMC Genomics 2016 06 17;17:467. Epub 2016 Jun 17.

CEIT, Parque Tecnológico de San Sebastián, Paseo Mikeletegi 48, 20009, San Sebastián, Gipuzkoa, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12864-016-2816-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912780PMC
June 2016

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.

J Thorac Oncol 2016 Apr 1;11(4):524-36. Epub 2016 Feb 1.

Department of Immunology, Center for Applied Medical Research, Universidad de Navarra; Department of Oncology and Clinical Trial Unit, Clínica Universidad de Navarra. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.01.013DOI Listing
April 2016

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

PLoS One 2015 23;10(3):e0119878. Epub 2015 Mar 23.

Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, Spain; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119878PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370816PMC
March 2016

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.

PLoS One 2015 27;10(4):e0124670. Epub 2015 Apr 27.

Biomarkers Laboratory, Program of Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain; Department of Histology and Pathology, School of Medicine, University of Navarra, 31008 Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0124670PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411155PMC
February 2016

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes.

J Thorac Cardiovasc Surg 2015 Oct 9;150(4):986-92.e1-11. Epub 2015 Jun 9.

Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), Pamplona, Spain; Navarra's Health Research Institute (IDISNA), Pamplona, Spain; Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2015.06.001DOI Listing
October 2015

Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.

Eur J Cancer 2015 Sep 30;51(14):1897-903. Epub 2015 Jul 30.

Program in Solid Tumor and Biomarkers, Center for Applied Medical Research, University of Navarra, Pamplona 31008, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.07.015DOI Listing
September 2015

The role of complement in tumor growth.

Adv Exp Med Biol 2014 ;772:229-62

Oncology Division (CIMA), and Department of Biochemistry and Genetics (School of Science), University of Navarra, Pamplona, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4614-5915-6_11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379038PMC
July 2014

Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration.

Nanomedicine (Lond) 2014 Jul 28;9(14):2109-21. Epub 2014 Jan 28.

Department of Pharmacy & Pharmaceutical Technology, School of Pharmacy, University of Navarra, Calle de Irunlarrea, 1, 31080, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nnm.13.199DOI Listing
July 2014

TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.

Mol Cancer Res 2014 May 24;12(5):660-9. Epub 2014 Feb 24.

Authors' Affiliations: Oncology Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona; 2Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain; 3Nuffield Department of Clinical Laboratory Sciences; 4Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital; 5Department of Medical Oncology, University of Oxford, The Churchill Hospital, Oxford, United Kingdom; 6Department of Rheumatology and Immunology, Shandong Provincial Hospital, Shandong University, Jinan, China; and 7Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-13-0481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207305PMC
May 2014

Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.

Cancer Res 2014 Feb 26;74(4):1105-15. Epub 2013 Dec 26.

Authors' Affiliations: Division of Oncology, Center for Applied Medical Research (CIMA); Departments of Histology and Pathology and Biochemistry and Genetics, Schools of Science and Medicine, University of Navarra, Pamplona; and CEIT and TECNUN, University of Navarra, San Sebastian, Spain.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2013/12/24/0
Web Search
http://cancerres.aacrjournals.org/content/74/4/1105.full.pdf
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-13-1481DOI Listing
February 2014

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

J Natl Cancer Inst 2013 Sep 12;105(18):1385-93. Epub 2013 Aug 12.

Affiliations of authors: Division of Oncology, Center for Applied Medical Research, Pamplona, Spain (DA, MJP, LC, JA, LMM, RP); Department of Histology and Pathology (MJP, JA, LMM) and Department of Biochemistry and Genetics (RP) School of Medicine, University of Navarra, Pamplona, Spain; Department of Oncology (JLP), Department of Pathology (MDL), Department of Thoracic Surgery (WT), Department of Pulmonary Medicine (JPdT, JJZ) Clínica Universidad de Navarra, Pamplona, Spain; Thoracic Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN (PPM); Department of Medicine, University of Valencia, Valencia, Spain (CC); Department of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain (CC); Molecular Oncology Laboratory, Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain (EJL).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776260PMC
September 2013

Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.

Int J Cancer 2013 May 20;132(9):1986-95. Epub 2012 Oct 20.

Oncology Division, Center for Applied Medical Research (CIMA), University of Navarra, 55 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.27881DOI Listing
May 2013

Multiscale in situ analysis of the role of dyskerin in lung cancer cells.

Integr Biol (Camb) 2013 Feb;5(2):402-13

Oncology Division, Center for Applied Medical Research, CIMA, University of Navarra, Avda. Pio XII 55, Pamplona 31008, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c2ib20219kDOI Listing
February 2013

Complement inhibition in cancer therapy.

Semin Immunol 2013 Feb 24;25(1):54-64. Epub 2013 May 24.

Oncology Division, Center for Applied Medical Research-CIMA, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.smim.2013.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3733085PMC
February 2013

Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses.

Vaccine 2012 Apr 2;30(18):2848-58. Epub 2012 Mar 2.

Gene Therapy and Hepatology Area and Oncology Area, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2012.02.052DOI Listing
April 2012

Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Clin Cancer Res 2011 Jun 3;17(12):4155-66. Epub 2011 May 3.

Departments of Oncology, Pathology, and Thoracic Surgery, Clínica Universidad de Navarra; Division of Oncology, Center for Applied Medical Research (CIMA), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-3381DOI Listing
June 2011

VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.

Mol Cancer 2010 Dec 31;9:320. Epub 2010 Dec 31.

Laboratory of Novel Therapeutic Targets, Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://molecular-cancer.biomedcentral.com/articles/10.1186/1
Publisher Site
http://dx.doi.org/10.1186/1476-4598-9-320DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022671PMC
December 2010

Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer.

Cancer Epidemiol Biomarkers Prev 2010 Oct 27;19(10):2665-72. Epub 2010 Aug 27.

Division of Oncology, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-10-0467DOI Listing
October 2010

The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression.

Clin Cancer Res 2010 Aug 3;16(16):4113-25. Epub 2010 Aug 3.

Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0076DOI Listing
August 2010

TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Mol Cancer 2010 May 28;9:130. Epub 2010 May 28.

Division of Oncology, Center for Applied Medical Research, Universidad de Navarra, Pío XII 55, Pamplona, 31008, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-9-130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900244PMC
May 2010

Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.

Cancer Immunol Immunother 2009 Nov 4;58(11):1771-80. Epub 2009 Mar 4.

Department of Laboratory Medicine, Section of Medical Protein Chemistry, University Hospital, UMAS, Lund University, entrance 46, 205 02 Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-009-0685-8DOI Listing
November 2009

Current challenges in lung cancer early detection biomarkers.

Eur J Cancer 2009 Sep;45 Suppl 1:377-8

Oncology Division, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0959-8049(09)70055-3DOI Listing
September 2009

A gene-alteration profile of human lung cancer cell lines.

Hum Mutat 2009 Aug;30(8):1199-206

Lung Cancer Group, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.21028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900846PMC
August 2009

Alternative splicing in lung cancer.

J Thorac Oncol 2009 Jun;4(6):674-8

Division of Oncology, Center for Applied Medical Research and School of Medicine, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181a520dcDOI Listing
June 2009

Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Hum Mutat 2008 May;29(5):617-22

Lung Cancer Group, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncologicas(CNIO), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.20730DOI Listing
May 2008

Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells.

Int J Cancer 2008 Apr;122(7):1512-20

Division of Oncology, CIMA, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.23236
Publisher Site
http://dx.doi.org/10.1002/ijc.23236DOI Listing
April 2008

Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.

Mol Immunol 2008 Jan 4;45(1):169-79. Epub 2007 Jun 4.

Lund University, Department of Laboratory Medicine, Section of Clinical Chemistry, University Hospital, S-205 02 Malmö, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2007.04.025DOI Listing
January 2008

Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.

J Immunol 2007 May;178(9):5991-8

Division of Oncology, Center for Applied Medical Research, School of Medicine, University of Navarre, Pamplona 31008, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.178.9.5991DOI Listing
May 2007

Alternative splicing: an emerging topic in molecular and clinical oncology.

Lancet Oncol 2007 Apr;8(4):349-57

Oncology Division, Centre for Applied Medical Research, School of Medicine, University of Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(07)70104-3DOI Listing
April 2007

Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features.

Cancer Epidemiol Biomarkers Prev 2006 Feb;15(2):373-80

Oncology Division, Center for Applied Medical Research, Clínica Universitaria de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://cebp.aacrjournals.org/cgi/doi/10.1158/1055-9965.EPI-0
Publisher Site
http://dx.doi.org/10.1158/1055-9965.EPI-05-0320DOI Listing
February 2006

Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing.

Mol Carcinog 2004 Dec;41(4):187-96

Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado 802262, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mc.20053DOI Listing
December 2004

Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene.

Oncogene 2004 May;23(22):4037-40

Lymphoma and Lung Cancer Group, Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, Calle Melchor Fernández Almagro, 3, 28029 Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1207502
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1207502DOI Listing
May 2004

Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer.

Lung Cancer 2003 Aug;41(2):131-43

Department of Histology and Pathology, School of Medicine and University Hospital, University of Navarra, 1 Irunlarrea Street, P.O. Box 177, 31080 Pamplona, Spain.

View Article

Download full-text PDF

Source
August 2003

Mapping of the adrenomedullin-binding domains in human complement factor H.

Hypertens Res 2003 Feb;26 Suppl:S55-9

Cell and Cancer Biology Branch, Vascular Biology Faculty, National Cancer Institute, NIH, Building 10, Room 13N262, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
February 2003

Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo.

Mol Cell Endocrinol 2003 Jan;199(1-2):179-87

Department of Urology, Northwestern University Medical School, Tarry 11-715, 303 E. Chicago Ave., Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
January 2003

The effects of adrenomedullin overexpression in breast tumor cells.

J Natl Cancer Inst 2002 Aug;94(16):1226-37

Cell and Cancer Biology Branch and Vascular Biology Faculty, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/94.16.1226DOI Listing
August 2002

Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma.

Microsc Res Tech 2002 Apr;57(1):23-7

Department of Biochemistry and Carcinogenesis Unit, University of Navarra, Pamplona, 31080 Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jemt.10047
Publisher Site
http://dx.doi.org/10.1002/jemt.10047DOI Listing
April 2002

Adrenomedullin functions as an important tumor survival factor in human carcinogenesis.

Microsc Res Tech 2002 Apr;57(2):110-9

Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jemt.10059DOI Listing
April 2002